{"result_id": "126045", "URL": "https://covid19criticalcare.com/references/vaccine-effectiveness-against-sars-cov-2-infection-with-the-omicron-or-delta-variants-following-a-two-dose-or-booster-bnt162b2-or-mrna-1273-vaccination-series-a-danish-cohort-study/", "timestamp": "2023-04-25 15:11:09 CEST+0200", "meta": {"description": "In this brief communication we are showing original research results with early estimates from Danish nationwide databases of vaccine effectiveness (VE) against the novel SARS-CoV-2 Omicron variant (B.1.1.529) up to five months after a primary vaccination series with the BNT162b2 or mRNA-1273 vaccines.", "lang": "en", "keywords": "", "favicon": "https://covid19criticalcare.com/wp-content/uploads/2022/09/cropped-new_favicon_2022-32x32.png", "canonical": "https://covid19criticalcare.com/references/vaccine-effectiveness-against-sars-cov-2-infection-with-the-omicron-or-delta-variants-following-a-two-dose-or-booster-bnt162b2-or-mrna-1273-vaccination-series-a-danish-cohort-study/", "encoding": "utf-8"}, "image": null, "domain": "covid19criticalcare.com", "title": "Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A danish cohort study", "cleaned_text": "In this brief communication we are showing original research results with early estimates from Danish nationwide databases of vaccine effectiveness (VE) against the novel SARS-CoV-2 Omicron variant (B.1.1.529) up to five months after a primary vaccination series with the BNT162b2 or mRNA-1273 vaccines.\n\nOur study provides evidence of protection against infection with the Omicron variant after completion of a primary vaccination series with the BNT162b2 or mRNA-1273 vaccines; in particular, we found a VE against the Omicron variant of 55.2% (95% confidence interval (CI): 23.5 to 73.7%) and 36.7% (95% CI: 69.9 to 76.4%) for the BNT162b2 and mRNA-1273 vaccines, respectively, in the first month after primary vaccination. However, the VE is significantly lower than that against Delta infection and declines rapidly over just a few months. The VE is re-established upon revaccination with the BNT162b2 vaccine (54.6%, 95% CI: 30.4 to 70.4%).", "opengraph": {"locale": "en_US", "type": "article", "title": "Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A danish cohort study", "description": "Hansen CH, Schelde AB, Mousten-Helm IR et al. doi: https://doi.org/10.1101/2021.12.20.21267966 Abstract\nIn this brief communication we are showing original research results with early estimates from Danish nationwide databases of vaccine effectiveness (VE) against the novel SARS-CoV-2 Omicron variant (B.1.1.529) up to five months after a primary vaccination series with the BNT162b2 or mRNA-1273 vaccines.\n\nOur study provides", "url": "https://covid19criticalcare.com/references/vaccine-effectiveness-against-sars-cov-2-infection-with-the-omicron-or-delta-variants-following-a-two-dose-or-booster-bnt162b2-or-mrna-1273-vaccination-series-a-danish-cohort-study/", "site_name": "FLCCC | Front Line COVID-19 Critical Care Alliance", "article:publisher": "https://www.facebook.com/FrontlineCovid19CriticalCare/"}, "tags": ["answering audience questions"], "tweets": [], "movies": [], "links": [], "authors": [], "publish_date": null}